Search Result

Results for "

FcεRIα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Aminoacyl-tRNA Synthetase (1) Apoptosis (12) Autophagy (1) Biochemical Assay Reagents (6) BMX Kinase (1) Btk (3) Carbonic Anhydrase (2) CD19 (1) CD20 (1) CD28 (1) CD3 (4) CD38 (1) CD47 (1) CD73 (1) CTLA-4 (4) CXCR (2) EGFR (4) Endogenous Metabolite (2) Estrogen Receptor/ERR (6) Factor VIII (1) FAK (1) FGFR (1) Fungal (1) GCGR (1) HIV (3) ICMT (1) Immune Checkpoint (1) Insulin Receptor (1) Interleukin Related (4) Isotope-Labeled Compounds (2) LAG-3 (1) Microtubule/Tubulin (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (2) Parasite (1) PD-1/PD-L1 (5) PDI (2) PKC (1) PROTACs (1) Reactive Oxygen Species (2) Reverse Transcriptase (1) SARS-CoV (2) STAT (1) Syk (1) TAM Receptor (1) TGF-β Receptor (1) TNF Receptor (8) Toll-like Receptor (TLR) (1) VEGFR (3) Wnt (1)
By Research Areas:	Cancer (61) Cardiovascular Disease (6) Infection (14) Inflammation/Immunology (40) Metabolic Disease (12)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

1472

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

FC-116	Reactive Oxygen Species Apoptosis Microtubule/Tubulin	Cancer
FC-11 is a Tubulin inhibitor that effectively inhibits tumor growth in mice. FC-11 can also induce endoplasmic reticulum (ER) stress to generate excess reactive oxygen species (ROS), leading to mitochondrial damage, thereby promoting apoptosis in colorectal cancer (CRC) cells by targeting microtubules. FC-11 can be used in cancer research .

FC-11	FAK PROTACs	Cancer
FC-11 is a PROTAC FAK degrader (DC₉₀: 1 nM) . FC-11 contains CRBN ligand Pomalidomide (HY-10984), linker and FAK ligand PF562271 (HY-10459) .

(E/Z)-E64FC26	Apoptosis PDI	Cancer
(E/Z)-E64FC26 is a mixture complex of E-E64FC26 and Z-E64FC26. E64FC26 (E-E64FC26) is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6. E64FC26 shows anti-myeloma activity .

FC9402	Others	Cardiovascular Disease
FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation .

Fluorinert FC-40 Perfluoro-compound FC-40	Biochemical Assay Reagents	Others
Fluorinert FC-40 is a non-conductive liquid containing a mixture of fluorinated compounds. It is commonly used as a cooling and heat transfer fluid in electronics, especially in high-performance computer systems and electronic components that generate a lot of heat. Fluorinert FC-40 has various properties that make it ideal for these applications, including its low viscosity, high thermal stability and excellent dielectric strength. In addition, it can be used as an inert solvent in chemical reactions and a lubricant in mechanical systems.

Notoginsenoside Fc	Autophagy	Cardiovascular Disease
Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .

FC14-584B	Carbonic Anhydrase	Infection
FC14-584B, a dithiocarbamate, is a β-Carbonic Anhydrase inhibitor. FC14-584B inhibits the growth of trophozoites. FC14-584B can be used for the research of tuberculosis .

FC131	CXCR HIV	Infection
FC131 is a potent CXCR4 antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

FC11409B	Carbonic Anhydrase	Cancer
FC11409B is an ureido-sulfamate carbonic anhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O₂) and normoxic conditions (21% O₂). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .

Fusarochromanone FC-101	Reactive Oxygen Species	Cardiovascular Disease Cancer
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity . Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS) .

Luviquat FC 550	Biochemical Assay Reagents	Others
Luviquat FC 550 is a cationic polymer commonly used in a variety of personal care and cosmetics. It is a viscous liquid containing quaternary ammonium groups which give it a positive charge. Luviquat FC 550 has a variety of properties suitable for these applications including its ability to provide conditioning, antistatic and film-forming properties to hair and skin. In addition, it is used as a binder in oral care products and as a flocculant in industrial water treatment.

Fc 11a-2	NOD-like Receptor (NLR)	Inflammation/Immunology
Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis .

Anti-IgG-Fc (Human)	Biochemical Assay Reagents	Others
Anti-IgG-Fc (Human) is an antibody against human IgG1 .

FC382K10W15 TFA	GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

Briobacept BR 3FC	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .

E64FC26 2 Publications Verification	Apoptosis PDI	Cancer
E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC₅₀s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity .

Davoceticept ALPN-202; CD80 vIgD-Fc	CTLA-4	Others
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a CXCR4 antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

Dexelvucitabine Reverset; d-d4FC	Reverse Transcriptase HIV	Infection
Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active nucleoside reverse transcriptase inhibitor. Dexelvucitabine is a powerful agent against HIV-1-resistant viruses containing a thymidine analog and/or M184V mutation in the viral polymerase. Dexelvucitabine is a 2′-Deoxycytidine antiretroviral agent .

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

Farnesylcysteine	ICMT	Metabolic Disease
Farnesylcysteine (FC) is a competitive inhibitor of ICMT. The fcly mutant has quantitatively low farnesylcysteine (FC) lyase activity and an enhanced response to ABA. Farnesylcysteine induces an ABA hypersensitive phenotype in Arabidopsis thaliana .

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

Conbercept KH902	VEGFR	Others
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc .

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function .

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

Efmoroctocog alfa	Factor VIII	Others
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .

IgdE protease	Biochemical Assay Reagents	Inflammation/Immunology
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix	Apoptosis	Inflammation/Immunology Cancer
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

BTK-IN-11	Btk	Inflammation/Immunology Cancer
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .

Lenercept p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1	TNF Receptor	Inflammation/Immunology
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

Acazicolcept ALPN-101	CD28	Inflammation/Immunology
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .

Eflepedocokin alfa	STAT	Inflammation/Immunology
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human *IgG2-Fc* domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .

hIgG-hFc receptor-IN-1	Others	Inflammation/Immunology
hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC₅₀ of 2 μM .

Prolgolimab BCD-100	PD-1/PD-L1	Cancer
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

Cat. No.	Product Name	Type

HY-D2341

6FC-GABA-Taxol

Fluorescent Dyes/Probes

6FC-GABA-Taxol is a fluorescent probe with cell permeability, which is formed by connecting 6FC to the anticancer drug Taxol (HY-B0015) via γ-aminobutyric acid (GABA). 6FC-GABA-Taxol can bind to microtubules in living cells and image them through confocal microscopy. Additionally, 6FC-GABA-Taxol enables the quantification of microtubule binding using flow cytometry without the addition of efflux inhibitors .

Cat. No.	Product Name	Type

HY-W127717

Fluorinert FC-40

Perfluoro-compound FC-40

Thickeners

Fluorinert FC-40 is a non-conductive liquid containing a mixture of fluorinated compounds. It is commonly used as a cooling and heat transfer fluid in electronics, especially in high-performance computer systems and electronic components that generate a lot of heat. Fluorinert FC-40 has various properties that make it ideal for these applications, including its low viscosity, high thermal stability and excellent dielectric strength. In addition, it can be used as an inert solvent in chemical reactions and a lubricant in mechanical systems.

HY-NP006

Protein A

SPA

Native Proteins

Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

HY-W016916

Trifluoromethanesulfonic acid sodium Triflic acid sodium; Perfluoromethanesulfonic acid sodium; Fluorad FC 24 sodium	Biochemical Assay Reagents
Sodium trifluoromethanesulfonate is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

HY-W020983

Trifluoromethanesulfonic acid silver Triflic acid silver; Perfluoromethanesulfonic acid silver; Fluorad FC 24 silver	Biochemical Assay Reagents
Trifluoromethanesulfonic acid (Triflic acid) silver, a perfluoroalkanesulfonic acid, is one of the superior catalysts for C- or O-acylation .

HY-W250194

Luviquat FC 550

Surfactants

Luviquat FC 550 is a cationic polymer commonly used in a variety of personal care and cosmetics. It is a viscous liquid containing quaternary ammonium groups which give it a positive charge. Luviquat FC 550 has a variety of properties suitable for these applications including its ability to provide conditioning, antistatic and film-forming properties to hair and skin. In addition, it is used as a binder in oral care products and as a flocculant in industrial water treatment.

Cat. No.	Product Name	Target	Research Area

HY-P1104A

FC131 TFA	CXCR HIV	Infection
FC131 TFA is a CXCR4 antagonist, inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4, with an IC₅₀ of 4.5 nM. Anti-HIV activity .

HY-P5755

SWELYYPLRANL-NH2	Peptides	Cancer
SWELYYPLRANL-NH2 is an E-cadherin and N-cadherin antagonist. SWELYYPLRANL-NH2 inhibits phage clone binding to E- or N-cad/Fc chimeric protein (IC₅₀: 0.7 and 0.09 μM respectively). SWELYYPLRANL-NH2 inhibits cell aggregation. SWELYYPLRANL-NH2 can be used to promote drug delivery through epithelial and endothelial permeability barriers .

HY-P1104

FC131	CXCR HIV	Infection
FC131 is a potent CXCR4 antagonist. FC131 inhibits [ ¹²⁵I]-SDF-1 binding to CXCR4 with an IC₅₀ of 4.5 nM. FC131 has anti-HIV activity .

HY-P5161A

FC382K10W15 TFA	GCGR	Metabolic Disease
FC382K10W15 TFA is a glucagon analogue and GLP-1R/GCGR agonist. FC382K10W15 TFA can be used in type 2 diabetes research .

HY-P5161

FC382K10W15	Peptides	Metabolic Disease
FC382K10W15 is a glucagon derivative useful for diabetes research .

HY-P10722

Efpegerglucagon	Peptides	Inflammation/Immunology
Efpegerglucagon is an Fc fragment of human immunoglobulin G4 (IgG4), formed as a disulfide-bonded dimer. One of the Fc chains is linked via a bifunctional maleimide-polyethylene glycol-aldehyde linker to a glucagon peptide analogue .

HY-P10085

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

HY-P2665

Lymphocyte activating pentapeptide	Peptides	Others
Lymphocyte activating pentapeptide is a short peptide sequence found in the Fc region of human IgG1 that has the ability to activate lymphocytes. Lymphocyte activating pentapeptide can be used to study the activation mechanisms of B cells and T cells, and their role in immune responses .

HY-P10544

Humanized anti-tac (HAT) binding peptide	Peptides	Others
Humanized anti-tac (HAT) binding peptide is a peptide that can specifically bind to the Fc region of HAT. HAT is a humanized monoclonal antibody against the low affinity p55 subunit of the interleukin IL-2 receptor. Humanized anti-tac (HAT) binding peptide can be used to develop affinity chromatography media to purify specific monoclonal antibodies .

HY-P10492

Tregitope 289	Peptides	Others Metabolic Disease
Tregitope 289 is a peptide derived from the Fc region of immunoglobulin G (IgG) and is a highly conserved T cell epitope that stimulates the expansion of natural regulatory T cells. Co-delivery of Tregitope 289 with type 1 diabetes (T1D) antigens delays the development of hyperglycemia and reduces the incidence of diabetes in the NOD mouse model. Tregitope 289 can be used to study T1D and other autoimmune diseases .

HY-P5755A

SWELYYPLRANL-NH2 TFA	Peptides	Cancer
SWELYYPLRANL-NH2 TFA is an E-cadherin and N-cadherin antagonist. SWELYYPLRANL-NH2 TFA inhibits phage clone binding to E- or N-cad/Fc chimeric protein (IC₅₀: 0.7 and 0.09 μM respectively). SWELYYPLRANL-NH2 TFA inhibits cell aggregation. SWELYYPLRANL-NH2 can be used to promote drug delivery through epithelial and endothelial permeability barriers .

Cat. No.	Product Name	Target	Research Area

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	Inhibitory Antibodies	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99529

Valziflocept BAX1810; TAK-752	Inhibitory Antibodies	Inflammation/Immunology
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P99879

Efbemalenograstim alfa Benegrastim; Bineuta; F 627	Inhibitory Antibodies	Inflammation/Immunology Cancer
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .

HY-P99975

Anti-IgG-Fc (Human)	Biochemical Assay Reagents	Others
Anti-IgG-Fc (Human) is an antibody against human IgG1 .

HY-P99381

XmAb 5592	Inhibitory Antibodies	Cancer
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP) .

HY-P99487

Briobacept BR 3FC	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P99833

Cosibelimab CK-301; TG-1501	PD-1/PD-L1	Cancer
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Wnt	Cancer
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P990005

Mouse IgG2a Fc, Isotype Control	Inhibitory Antibodies	Others
Mouse IgG2a Fc, Isotype Control, is a Fc fragment of mouse IgG2a only and does not contain the Fab fragments. The molecular mass is about 34 kDa.

HY-P99844

Davoceticept ALPN-202; CD80 vIgD-Fc	CTLA-4	Others
Davoceticept (ALPN-202; CD80 vIgD-Fc) is a monoclonal antibody targeting CTLA-4. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P990413

Anti-Fc gamma R1 Antibody	Inhibitory Antibodies	Inflammation/Immunology

HY-P99037

Nipocalimab 1 Publications Verification M281	Inhibitory Antibodies	Inflammation/Immunology
Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6 .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P990863

Anti-CD32/FcγRIIA Antibody (IV.3)	Inhibitory Antibodies	Others
Anti-CD32/FcγRIIA Antibody (IV.3) is a kind of mouse IgG2b chimeric antibody, targeting to human CD32/FcγRIIA. The recommend isotype control of Anti-CD32/FcγRIIA Antibody (IV.3): Mouse IgG2b kappa, Isotype Control (HY-P99982).

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99437

Anbenitamab KN-026	EGFR	Cancer
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P990076

Lorukafusp alfa 14.18 mAb; hu14.18-IL2; EMD 273063	Inhibitory Antibodies	Cancer
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity .

HY-P99947

Rimteravimab XVR011	SARS-CoV	Infection
Rimteravimab (XVR011) is a bivalent VHH-Fc antibody with potent neutralizing activity with high stability, broad coverage and silenced Fc effector functions against the disease caused by SARS-CoV-2 .

HY-P99830

Conbercept KH902	VEGFR	Others
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc .

HY-P99489

Budigalimab ABBV 181; PR 1648817	PD-1/PD-L1	Cancer
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an *Fc-FGF21* fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P99518

Taldefgrobep alfa BMS 986089; RG 6206; RO 7239361; BHV2000	Inhibitory Antibodies	Others
Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	CD38	Cancer
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-112998

Efmoroctocog alfa	Factor VIII	Others
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .

HY-P9981

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix	Apoptosis	Inflammation/Immunology Cancer
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .

HY-P99445

Asunercept APG101; CAN008	TNF Receptor	Inflammation/Immunology Cancer
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99932

Eftansomatropin alfa	Inhibitory Antibodies	Others
Eftansomatropin alfa is an antibody targeting the growth hormone receptor (GSH). Eftansomatropin alfa is a fusion protein of GH1 and IGHG4 Fc .

HY-P99692

Lenercept p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1	TNF Receptor	Inflammation/Immunology
Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .

HY-P99467

Beludavimab BMS 4182137; VIR 7832	SARS-CoV	Infection
Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC₅₀ value of 14.9 ng/mL and a K_d of 0.21 nM .

HY-P99420

Acazicolcept ALPN-101	CD28	Inflammation/Immunology
Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities .

HY-P99876

Efaprinermin alfa OMP-336B11	Inhibitory Antibodies	Others
Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody targeting TNFRSF18. Efaprimermin alfa is a GITR ligand-Fc fusion protein .

HY-P99917

Eflepedocokin alfa	STAT	Inflammation/Immunology
Eflepedocokin alfa is a recombinant fusion protein with potential cell protective activity. Eflepedocokin alfa consists of human IL-22 fused to human *IgG2-Fc* domain. Eflepedocokin alfa leads to the activation of IL-22/IL-22R-mediated signal transduction pathways as well as STAT3. Eflepedocokin alfa plays a role in immune response and bacterial infection, enhancing intestinal barrier function, intestinal immunity, and tissue repair .

HY-P99807

Prolgolimab BCD-100	PD-1/PD-L1	Cancer
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .

HY-P9979

Rozanolixizumab UCB7665	Inhibitory Antibodies	Inflammation/Immunology
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99572

Tecaginlimab BNT-312; DuoBody-CD40x-4-1BB; GEN1042	TNF Receptor	Inflammation/Immunology Cancer
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .

HY-P99308

Ocaratuzumab AME 133v; LY 2469298; Humanized Anti-MS4A1 Recombinant Antibody	CD20	Cancer
Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a K_d of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC) .

HY-P99877

Efavaleukin alfa AMG592	Inhibitory Antibodies	Others
Efavaleukin alfa (AMG592) is a human monoclonal antibody. Efavaleukin alfa is composed of the IGHG1 Fc fragment fused to IL-2. The expression system of Efavaleukin alfa is usually CHO (Chinese Hamster Ovary) cells .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25	Inhibitory Antibodies	Inflammation/Immunology Cancer
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Apoptosis	Inflammation/Immunology Cancer
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99030

Margetuximab	EGFR	Cancer
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P990067

Evunzekibart ATOR-1017	TNF Receptor	Cancer
Evunzekibart (ATOR-1017) is an Fc-γ receptor conditional 4-1BB agonist and IgG4-type antibody. Evunzekibart can be used as monotherapy or in combination with anti-PD1 to exert anticancer activity.

HY-P99763

Ociperlimab BGB-A1217	Inhibitory Antibodies	Cancer
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (K_D = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .

HY-P99701

Letolizumab BMS-986004	TNF Receptor	Inflammation/Immunology
Letolizumab (BMS-986004) is a monoclonal antibody targeting CD40L, which is produced to express mutant IgG1 lacking effector function, including Fc binding and complement fixation. Letolizumab reduces rejection, thromboembolism and prolongs the survival time .

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	EGFR	Cancer
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-P99568

Telitacicept RC18	Inhibitory Antibodies	Inflammation/Immunology
Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease .

HY-108822

Rilonacept Arcalyst; IL 1 Trap; Interleukin 1 Trap	Interleukin Related	Inflammation/Immunology
Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2531

Notoginsenoside Fc	Cardiovascular Disease Triterpenes Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Araliaceae	Autophagy
Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy .

HY-P99879

Efbemalenograstim alfa Benegrastim; Bineuta; F 627	Classification of Application Fields Disease Research Fields Cancer	Others
Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells .

HY-P99833

Cosibelimab CK-301; TG-1501	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Cosibelimab (CK-301; TG-1501) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab has a functional Fc domain and is capable of inducing ADCC and complement-dependent cytotoxicity (CDC)-mediated killing of PD-L1 ⁺ cell lines, including lymphoma cells .

HY-P99667

Ipafricept 1 Publications Verification OMP-54F28; FZD8-Fc	Classification of Application Fields Disease Research Fields Cancer	Wnt
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

HY-P9954

Catumaxomab	Classification of Application Fields Disease Research Fields Cancer	CD3
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99437

Anbenitamab KN-026	Classification of Application Fields Disease Research Fields Cancer	EGFR
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research .

HY-P99489

Budigalimab ABBV 181; PR 1648817	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Budigalimab (ABBV 181; PR 1648817) is a humanized IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function .

HY-136901

Fusarochromanone FC-101	Cardiovascular Disease Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Reactive Oxygen Species
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity . Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS) .

HY-P99562

Tidutamab XmAb-18087	Classification of Application Fields Disease Research Fields Cancer	CD3
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P9976A

Isatuximab (anti-CD38) 1 Publications Verification	Classification of Application Fields Disease Research Fields Cancer	CD38
Isatuximab (anti-CD38) is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38.Isatuximab induces tumor cell killing via fragment crystallizable (Fc)-dependent or Fc-independent mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) .

HY-P9981

Tafasitamab XmAb5574; MOR00208; Tafasitamab-cxix	Classification of Application Fields Disease Research Fields Cancer	Apoptosis
Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19 .

HY-P99445

Asunercept APG101; CAN008	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Asunercept (APG101; CAN008) is a soluble CD95-Fc fusion protein targeting CD95L. Asunercept disrupts CD95/CD95L signaling by selectively binding to CD95L. Asunercept can be used in the research of glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) .

HY-P99807

Prolgolimab BCD-100	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma .

HY-P99181

Mupadolimab CPI-006	Classification of Application Fields Disease Research Fields Cancer	CD73
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99572

Tecaginlimab BNT-312; DuoBody-CD40x-4-1BB; GEN1042	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Tecaginlimab (BNT-312) is a Fc-inert bispecific antibody for dual targeting and conditional stimulation of CD40 and 4-1BB. Tecaginlimab can enhance priming and reactivation of tumor-specific immunity .

HY-P9950

Omalizumab 1 Publications Verification Olizumab; rhuMab-E25	Classification of Application Fields Disease Research Fields Cancer	Others
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a K_D of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a K_D of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research .

HY-P99332

Visilizumab Anti-Human CD3E Recombinant Antibody; HuM291	Classification of Application Fields Disease Research Fields Cancer	Apoptosis
Visilizumab (Anti-Human CD3E Recombinant Antibody) is a humanized low-Fc receptor binding anti-CD3 monoclonal IgG2 antibody. Visilizumab can be used for ulcerative colitis and Crohn's disease research .

HY-P99030

Margetuximab	Classification of Application Fields Disease Research Fields Cancer	EGFR
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC₅₀ value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer .

HY-P99763

Ociperlimab BGB-A1217	Classification of Application Fields Disease Research Fields Cancer	Others
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (K_D = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer .

HY-P9977

Amivantamab 1 Publications Verification JNJ-61186372	Classification of Application Fields Disease Research Fields Cancer	EGFR
Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .

HY-N6780

Ophiobolin B	Infection Microorganisms Classification of Application Fields Terpenoids Sesquiterpenes Source classification Disease Research Fields	Fungal
Ophiobolin B, a sesterterpene metabolite of Helminthosporium oryzae, inhibits proton extrusion from maize coleoptiles. Ophiobolin B inhibits fusicoccin (FC) promoted proton extrusion, potassium uptake and cell enlargement . The MIC values with the antifungal effect of Ophiobolins B on different zygomycetes is 25–50 μg/mL .

HY-N2932

β-Yohimbine Amsonin; Amsonine; NSC 93133	Apocynaceae Rauvolfia verticillata (Lour.) Baill. Structural Classification Alkaloids Aspidosperma ulei Markgr. Source classification Plants Indole Alkaloids	Parasite
β-Yohimbine (Amsonin) is an indole alkaloid that can be isolated from Aspidosperma ulei Markgr. β-Yohimbine shows antiplasmodial activity against the Chloroquine (HY-17589A)-resistant Fc M29-Cameroon strain (IC₅₀: > 1 μg/mL) .

HY-P99470

Benufutamab GEN1029	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor Apoptosis
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	Classification of Application Fields Disease Research Fields Cancer	VEGFR
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	Classification of Application Fields Disease Research Fields Cancer	VEGFR
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-P99777

Ontorpacept TTI-621	Classification of Application Fields Disease Research Fields Cancer	CD47
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity .

HY-P99814

Pavurutamab AMG-701	Classification of Application Fields Disease Research Fields Cancer	CD3
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-P99742

Mitazalimab ADC-1013; JNJ-64457107	Classification of Application Fields Disease Research Fields Cancer	TNF Receptor
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P99590

Sotatercept ACE-011	Cardiovascular Disease Classification of Application Fields Disease Research Fields Cancer	TGF-β Receptor
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-P99115

Envafolimab ASC 22; KN 035	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC₅₀ value of 5.25?nM. Envafolimab has the potential for the research of solid tumors .

HY-P99573

Tebotelimab MGD-013	Classification of Application Fields Disease Research Fields Cancer	LAG-3
Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC₅₀s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .

HY-P99463

Batiraxcept AVB-S6-500	Classification of Application Fields Disease Research Fields Cancer	TAM Receptor
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-P99661

Inbakicept	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .

HY-P99117

Cadonilimab AK104	Classification of Application Fields Disease Research Fields Cancer	PD-1/PD-L1 CTLA-4 Immune Checkpoint
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .

Species:	Human (689) Virus (42) Marmoset (1) Rhesus Macaque (84) Rat (164) Mouse (365) Cynomolgus (94) Rabbit (2) Canine (38) Pig (1)
Tag:	His (176) SUMO (2) Tag Free (13) Avi (95) Myc (4) HSA (1) GST (1) Fc (1376) Flag (8)
Source:	HEK293 (1437) E. coli Cell-free (1) CHO (6) CHO (7) Sf9 insect cells (12) P. pastoris (1) E. coli (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P7501

	Amyloid Precursor Protein, Human (HEK293, Fc) rHuAmyloid Precursor, C-Fc; Amyloid-Precursor	Human	HEK293
	Amyloid Precursor Protein, Human (HEK293, Fc) is an Amyloid Precursor (APP) protein with C-Fc. Amyloid Precursor Protein can be used for the study of brain development, learning and memory, synaptic plasticity, and neurodegeneration.

HY-P78700

	IgG2B Fc Protein, Llama IgG2B; IgG2b Fc	Others	HEK293
	IgG2B Fc Protein, Llama is the recombinant IgG2B Fc protein, expressed by HEK293 , with tag free. The total length of IgG2B Fc Protein, Llama is 243 a.a., with molecular weight of 35-40 kDa.

HY-P74320

	CD23/Fc epsilon RII Protein, Rat (HEK293, Fc) Low affinity immunoglobulin epsilon Fc receptor; BLAST-2; FCER2; CD23A	Rat	HEK293
	CD23, also known as Fc epsilon Receptor II (Fc epsilon RII), is a low-affinity receptor for immunoglobulin E (IgE) and complement receptor 2 (CR2/CD21). CD23 regulates IgE production and B-cell differentiation, aiding in IGE-dependent antigen uptake. CD23/Fc epsilon RII Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD23/Fc epsilon RII protein, expressed by HEK293 , with N-hFc labeled tag. The total length of CD23/Fc epsilon RII Protein, Rat (HEK293, Fc) is 282 a.a., with molecular weight of 60-75 kDa.

HY-P75212

	Fc epsilon RIA/FCER1A Protein, Mouse (HEK293, Fc) Fc epsilon RI alpha; FCE1A; FCER1A; FcERI; FceRIa	Mouse	HEK293
	Fc epsilon RIA/FCER1A protein is a high-affinity receptor for immunoglobulin epsilon/IgE and is critical for mediating IgE effector function. It activates and differentiates myeloid cells after binding IgE and cross-linking with antigens/allergens, causing mast cells, basophils, and eosinophils to secrete mediators and cytokines. Fc epsilon RIA/FCER1A Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Fc epsilon RIA/FCER1A protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P7471

	ALCAM/CD166 Protein, Human (HEK293, Fc) rHuCD166, C-Fc; ALCAM; CD-166	Human	HEK293
	ALCAM/CD166 Protein, Human (HEK293, Fc), a recombinant human CD166 produced in HEK293 cells, has an Fc fragment at the C-terminus. CD166, also known as activated leukocyte cell adhesion molecule (ALCAM), is expressed by various cells in several tissues including cancer.

HY-P7472

	ALCAM/CD166 Protein, Mouse (HEK293, Fc) rMuCD166, C-Fc; ALCAM; CD-166	Mouse	HEK293
	ALCAM/CD166 Protein, Mouse (HEK293, Fc) is a recombinant mouse CD166 expressed by HEK293 cells with C-Fc tag. CD166, a member of the immunoglobulin superfamily, is widely expressed in various tissues, such as neurons, fibroblasts, endothelial cells, and keratinocytes.

HY-P70491

	Fc gamma RIIB/CD32b Protein, Human (HEK293, His) Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b; IgG Fc Receptor II-b; CDw32; Fc-Gamma RII-b; Fc-Gamma-RIIb; FcRII-b; CD32; FCGR2B; FCG2; IGFR2	Human	HEK293
	Fc gamma RIIB/CD32b protein is a low-affinity receptor for immunoglobulin gamma and plays a key role in immune responses. It mediates phagocytosis of immune complexes and regulates antibody production by B cells. Fc gamma RIIB/CD32b Protein, Human (HEK293, His) is the recombinant human-derived Fc gamma RIIB/CD32b protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76800

	Fc gamma RIIB/CD32b Protein, Cynomolgus (HEK293, His) Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b; IgG Fc Receptor II-b; CDw32; Fc-Gamma RII-b; Fc-Gamma-RIIb; FcRII-b; CD32; FCGR2B; FCG2; IGFR2	Cynomolgus	HEK293
	Fc γ RIIB/CD32b proteins exhibit low affinity as complexes or receptors that aggregate the immunoglobulin γFc region. ITIM phosphorylated by Fc γ RIIB/CD32b recruits inositol phosphatases SHIP1 and SHIP2, inhibits Ras activation, down-regulates MAPK activity, reduces PLC-γ function, and results in PKC activation. Inhibition of MAP kinase pathway and anti-apoptotic kinase Akt inhibit cell proliferation and survival. Fc gamma RIIB/CD32b Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fc gamma RIIB/CD32b protein, expressed by HEK293 , with C-His labeled tag.

HY-P703901

	EPO Protein, Human (Fc) erythropoietin	Human	HEK293

HY-P78438

	Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, His-Avi) CD16; Fc gamma RIIIB; FCG3; Fc-gamma receptor IIIb (CD 16); Fc-gamma RIIIb; Fc-gamma RIII-beta; FCGR3B; FcgRIIIB; FCRIIIB; IGFR3; IgG Fc receptor III-1; CD16b (NA2); CD16B; FCG3B; FCG3; FCGR3; FCR-10; Fc-gamma RIII-β	Human	HEK293
	Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Fc gamma RIIIB/CD16b Protein, Human (NA2, HEK293, His-Avi) is 184 a.a., with molecular weight of 47-53 kDa.

HY-P7335

	CD47 Protein, Human (HEK293, Fc) rHuCD47, Fc Chimera; MER6; IAP; OA3	Human	HEK293
	CD47 Protein, Human (HEK293, Fc) is a polypeptide chain with the C-terminal human IgG1 Fc fragment produced in HEK293 cells. CD47 is a prominent target in cancer immunotherapy.

HY-P7395

	PD-1 Protein, Human (CHO, Fc) 2 Publications Verification rHuPD-1, Fc Chimera; PD1; CD279; PDCD1	Human	CHO
	PD-1 Protein, Human (CHO, Fc) suppress activating signals from the T cell receptor when bound by either of its ligands, programmed death-ligand 1 (PD-L1) or PD-L2.

HY-P702279

	CD64 Protein, Human (Cell-Free, His) High affinity immunoglobulin gamma Fc receptor I; Fc-gamma RI; FcRI; Fc-gamma RIA; FcgammaRIa; CD antigen CD64	Human	E. coli Cell-free
	CD64 protein, a high affinity receptor, mediates IgG effector functions, triggering antibody-dependent cellular cytotoxicity (ADCC). It interacts with IGHG1 and forms a signaling complex with FCERG1, contributing to immune responses. CD64 also interacts with FLNA, EPB41L2, LAT, PPL, HCK, and LYN to prevent degradation of FCGR1A and regulate immune function. CD64 Protein, Human (Cell-Free, His) is the recombinant human-derived CD64 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of CD64 Protein, Human (Cell-Free, His) is 359 a.a., with molecular weight of 46.9 kDa.

HY-P76799

	Fc gamma RIIB/CD32b Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b; IgG Fc Receptor II-b; CDw32; Fc-Gamma RII-b; Fc-Gamma-RIIb; FcRII-b; CD32; FCGR2B; FCG2; IGFR2	Cynomolgus	HEK293
	Fc γ RIIB/CD32b proteins exhibit low affinity as complexes or receptors that aggregate the immunoglobulin γFc region. ITIM phosphorylated by Fc γ RIIB/CD32b recruits inositol phosphatases SHIP1 and SHIP2, inhibits Ras activation, down-regulates MAPK activity, reduces PLC-γ function, and results in PKC activation. Inhibition of MAP kinase pathway and anti-apoptotic kinase Akt inhibit cell proliferation and survival. Fc gamma RIIB/CD32b Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived Fc gamma RIIB/CD32b protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P70705

	Fc gamma RIIIA/CD16a Protein, Human (HEK293, His) 1 Publications Verification Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A; CD16a Antigen; Fc-Gamma RIII-Alpha; Fc-Gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc Receptor III-2; CD16a; FCGR3A; CD16A; FCG3; FCGR3; IGFR3	Human	HEK293
	Fc gamma RIIIA/CD16a protein is a receptor for the Fc fragment of IgG and activates antibody-dependent cellular cytotoxicity (ADCC) upon binding to antigen-IgG complexes. It mediates IgG effector functions on NK cells, generating memory-like adaptive NK cells to efficiently eliminate virally infected cells. Fc gamma RIIIA/CD16a Protein, Human (HEK293, His) is the recombinant human-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Fc gamma RIIIA/CD16a Protein, Human (HEK293, His) is 192 a.a., with molecular weight of 36-44 kDa.

HY-P70708

	Fc gamma RIII/CD16 Protein, Mouse (HEK293, His) Low affinity immunoglobulin gamma Fc region receptor III; Fcgr3; Fc gamma Receptor III; CD-antigen 16; CD16; FcRIII; IgG Fc receptor III	Mouse	HEK293
	Fc gamma RIII/CD16 Protein, a low-affinity receptor for IgG1, IgG2a, and IgG2b, is crucial for mediating neutrophil activation in response to IgG complexes. It functions redundantly with Fcgr4 and interacts with INPP5D/SHIP1, emphasizing its involvement in intracellular signaling pathways linked to immune responses. Fc gamma RIII/CD16's significance lies in facilitating cellular activation triggered by immunoglobulin binding. Fc gamma RIII/CD16 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P78122

	Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA2, HEK293, His-Avi) CD16; Fc gamma RIIIB; FCG3; Fc-gamma receptor IIIb (CD 16); Fc-gamma RIIIb; Fc-gamma RIII-beta; FCGR3B; FcgRIIIB; FCRIIIB; IGFR3; IgG Fc receptor III-1; CD16b (NA2); CD16B; FCG3B; FCG3; FCGR3; FCR-10; Fc-gamma RIII-β	Human	HEK293
	Fc gamma RIIIB/CD16b Protein, a low-affinity receptor for IgG, binds complexed or monomeric IgG. Unlike Fc gamma RIIIA, it cannot mediate antibody-dependent cytotoxicity or phagocytosis. Instead, Fc gamma RIIIB may act as a trap for immune complexes, circulating without activating neutrophils. Existing as a monomer, it interacts with INPP5D/SHIP1, implying its role in intracellular signaling pathways linked to immune responses. Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA2, HEK293, His-Avi) is the recombinant human-derived Fc gamma RIIIB/CD16b protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Fc gamma RIIIB/CD16b Protein, Human (Biotinylated, NA2, HEK293, His-Avi) is 184 a.a., with molecular weight of 47-53 kDa.

HY-P70251

	IgG3 Fc Protein, Mouse (HEK293) rMuIg gamma-3 chain C region/IgG3 Fc; Ig gamma-3 chain C region,IgG3 Fc	Mouse	HEK293
	IgG3 Fc Protein is the high conserved Fc segment of IgG3 (Immunoglobulin G3). Mouse IgG3 Fc protein is involved in several processes, such as activation of immune response, B-cell signaling, complement activation. IgG3 Fc Protein, Mouse (HEK293) is the recombinant mouse-derived IgG3 Fc protein, expressed by HEK293 , with tag free. The total length of IgG3 Fc Protein, Mouse (HEK293) is 210 a.a., with molecular weight of ~31.0 kDa.

HY-P70711

	Fc gamma RIIA/CD32a Protein, Human (HEK293, His) Low affinity immunoglobulin gamma Fc region receptor II-a; IgG Fc receptor II-a; CDw32; Fc-gamma RII-a; Fc-gamma-RIIa; FcRII-a; CD32; FCGR2A; FCG2; FCGR2A1; IGFR2	Human	HEK293
	Fc gamma The RIIA/CD32a protein plays a key role as a low-affinity receptor that specifically binds to the Fc region of immunoglobulin gamma. It interacts with IgG to initiate cellular responses against pathogens, which is critical for immune regulation. Fc gamma RIIA/CD32a Protein, Human (HEK293, His) is the recombinant human-derived Fc gamma RIIA/CD32a protein, expressed by HEK293 , with C-6*His labeled tag and H167, , , , mutation.

HY-P7701

	Cadherin-3 Protein, Mouse (HEK293, Fc) rHuCadherin-3, C-Fc; Cadherin-3; Placental Cadherin; CDH3;	Mouse	HEK293
	Cadherin-3 Protein, Mouse (HEK293, Fc) is a recombinant mouse Cadherin-3 (P-cadherin) produced in HEK293 cells, with an Fc fragment at the C-terminus. Cadherin-3 is a classical cell-to-cell adhesion molecule with a homeostatic function in several normal tissues.

HY-P7797

	CD160 Protein, Rhesus macaque (HEK293, Fc) rRhCD160, C-Fc; CD160 antigen; CD160	Rhesus Macaque	HEK293
	CD160 Protein, Rhesus macaque (HEK293, Fc) is a recombinant rhesus macaque CD160 expressed in HEK 293 cells with a C-Fc tag at the C-terminus. CD160 Protein binds weakly to MHC I and stimulates NK and CD8⁺ T‐cell activation.

HY-P70771

	IgG4 Fc Protein, Human (HEK293) 1 Publications Verification Ig gamma-4 chain C region,IgG4 Fc	Human	HEK293
	The IgG4 Fc is the constant region of the immunoglobulin heavy chain, which forms the backbone of antibodies crucial in humoral immunity. B lymphocytes produce glycoprotein antibodies that initiate clonal expansion upon antigen binding. IgG4 Fc Protein, Human (HEK293) is the recombinant human-derived IgG4 Fc protein, expressed by HEK293 , with tag free. The total length of IgG4 Fc Protein, Human (HEK293) is 228 a.a., with molecular weight of ~32.0 kDa.

HY-P70453B

	Wnt3a Surrogate Protein, Human (HEK293, Fc) 2 Publications Verification Wnt3a Surrogate, Human (HEK293, Fc)	Human	HEK293
	Wnt3a Surrogate protein is a Wnt recombination protein that plays an important role in embryonic development, adult tissue homeostasis and injury repair. Wnt3a Surrogate protein, consisting of the domain and Fc portion of Wnt3a, helps organoids expand and maintain a source of Wnt. Organoids are a rapidly evolving model system for tissue development, and Wnt3a is considered as the essential protein for organoid growth. Wnt3a or the small molecule glycogen synthase kinase 3 (GSK3) inhibitor CHIR are commonly used as Wnt sources in experiments. However, the application of Wnt3a is hampered by Wnt lipidation, and cross-reactivity with Wnt frizzled (Fzd). Therefore, Wnt3a Surrogate protein was used instead of Wnt3a, as a water-soluble and Fzd-specific alternative Wnt agonist. And the Wnt3a Surrogate protein exhibits tissue selectivity consistent with Fzd isoform specificity. Wnt3a Surrogate Protein, Human (HEK293, Fc) is a recombinant Wnt3a protein of human origin. It is expressed by HEK293 cells with an Fc tag.

HY-P703903

	Fc epsilon RI Protein, Human (ECD) Fc fragment of IgE; high affinity I; receptor for; alpha polypeptide	Human	HEK293

HY-P72735

	Fc gamma RIIB/CD32b Protein, Mouse (HEK293, His) Low affinity immunoglobulin gamma Fc region receptor II; Fc-gamma-RIIB; Ly-17; CD32; Fcgr2	Mouse	HEK293
	Fc gamma RIIB/CD32b protein is a low-affinity receptor for immunoglobulin gamma and is involved in a variety of effector and regulatory functions. When co-aggregated with BCR, TCR and Fc receptors, it promotes endocytosis of soluble immune complexes (IIB2), modulates antibody production, and downregulates B-cell, T-cell and mast cell activation. Fc gamma RIIB/CD32b Protein, Mouse (HEK293, His) is the recombinant mouse-derived Fc gamma RIIB/CD32b protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P76207

	Fc gamma RIII/CD16 Protein, Mouse (Biotinylated, HEK293, His-Avi) Low affinity immunoglobulin gamma Fc region receptor III; Fcgr3; Fc gamma Receptor III; CD-antigen 16; CD16; FcRIII; IgG Fc receptor III	Mouse	HEK293
	Fc gamma RIII/CD16 Protein, a low-affinity receptor for IgG1, IgG2a, and IgG2b, is crucial for mediating neutrophil activation in response to IgG complexes. It functions redundantly with Fcgr4 and interacts with INPP5D/SHIP1, emphasizing its involvement in intracellular signaling pathways linked to immune responses. Fc gamma RIII/CD16's significance lies in facilitating cellular activation triggered by immunoglobulin binding. Fc gamma RIII/CD16 Protein, Mouse (Biotinylated, HEK293, His-Avi) is the recombinant mouse-derived Fc gamma RIII/CD16 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P72191

	Fc epsilon RIA/FCER1A Protein, Human (His-SUMO) Fc epsilon RI alpha; Fc epsilon RI alpha chain ; high affinity I; receptor for; alpha subunit; Fc fragment of IgE; high affinity I; receptor for; alpha polypeptide; Fc IgE receptor; alpha chain; Fc IgE receptor; alpha polypeptide; Fc-epsilon RI-alpha; FCE 1A; FCE1A; FCER1A; Fcer1a; FCERA_HUMAN; FceRI alpha; FcERI; high affinity IgE receptor;	Human	E. coli
	The Fc epsilon RIA/FCER1A protein is a high-affinity receptor for IgE and critically mediates IgE effector function in myeloid cells. After binding to IgE and cross-linking with antigen, it activates signaling pathways that induce myeloid cell activation and differentiation. Fc epsilon RIA/FCER1A Protein, Human (His-SUMO) is the recombinant human-derived Fc epsilon RIA/FCER1A protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of Fc epsilon RIA/FCER1A Protein, Human (His-SUMO) is 180 a.a., with molecular weight of ~37 kDa.

HY-P7317

	4-1BB/TNFRSF9 Protein, Human (CHO, Fc) rHu4-1BB, Fc Chimera; CD137; ILA	Human	CHO
	4-1BB (CD137; TNFRSF9), a receptor of TNFSF9/4-1BBL, belongs to the tumor necrosis factor (TNF) receptor superfamily. 4-1BB is helpful for T cell activation and development, and also induces peripheral mononuclear cell proliferation and migration to the tumor microenvironment. 4-1BB is also involved in enhancing Nrf2 and NF-κB pathway mediated apoptosis of endothelial cells. Human 4-1BB protein is a surface glycoprotein with a transmembrane domain (187-213 a.a.). 4-1BB/TNFRSF9 Protein, Human (CHO, Fc) is the extracellular part (L24-Q186) of 4-1BB protein, produced by HEK293 cells with C-terminal hFc-tag.

HY-P7366

	HVEM/TNFRSF14 Protein, Human (Sf9, Fc) rHuHVEM, Fc Chimera; TNFRSF14; TR2; CD270; HVEA	Human	Sf9 insect cells
	HVEM (herpes virus entry mediator, TNFRSF14, CD270) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). HVEM is a bidirectional molecular switch that transduces positive and negative signals. HVEM can deliver proinflammatory and survival signals when engaged by BTLA or LIGHT, stimulating lymphocyte proliferation, activation, and inducing inflammatory reactions. While, HVEM binds to CD160 and BTLA, inhibiting T- and B-lymphocyte activation and proliferation. HVEM/TNFRSF14 Protein, Human (Sf9, Fc) is a recombinant protein consisting of 146 amino acids (L39-K184) and is produced in Sf9 insect cells.

HY-P7401

	PVR/CD155 Protein, Human (HEK293, Fc) rHuPVR/CD155, Fc Chimera; Poliovirus receptor; NECL-5; PVS	Human	HEK293
	PVR/CD155 Protein, Human (HEK293, Fc), a Type I transmembrane glycoprotein in the immunoglobulin superfamily, is involved in the cellular poliovirus infection in primates and intestinal humoral immune responses.

HY-P7702

	Cadherin-6/KCAD Protein, Human (HEK293, Fc) rHuCadherin-6, C-Fc; Cadherin-6; Kidney Cadherin; CDH6	Human	HEK293
	Cadherin-6/KCAD Protein, Human (HEK293, Fc), a recombinant human Cadherin-6 produced in HEK293 cells, has an Fc fragment at the C-terminus. Cadherin-6 (CDH6) is a type 2 cadherin, which drives epithelial cells toward a mesenchymal condition (EMT) during embryonic development and it is aberrantly re-activated in cancer.

HY-P70356

	IL-11 Protein, Mouse (HEK293, Fc) rMuInterleukin-11/IL-11, Fc ; Interleukin-11; Il11; IL-11	Mouse	HEK293
	IL-11 protein is a multifunctional cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation to increase platelet production. It also contributes to liver cell proliferation in response to liver injury. IL-11 Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived IL-11 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of IL-11 Protein, Mouse (HEK293, Fc) is 178 a.a., with molecular weight of 50-60 kDa.

HY-P72657

	FCAR/CD89 Protein, Human (HEK293, His) Immunoglobulin Alpha Fc Receptor; IgA Fc Receptor; CD89; FCAR	Human	HEK293
	The FCAR/CD89 protein is crucial and can specifically bind to the Fc region of immunoglobulin α to promote the production of cytokines. FCAR/CD89 binds to the Fc epsilon RI gamma 2 receptor, induces gamma 2 tyrosine phosphorylation, and is complexly involved in signaling pathways and immune responses. FCAR/CD89 Protein, Human (HEK293, His) is the recombinant human-derived FCAR/CD89 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73533

	Zika virus Membrane protein (HEK293, Fc) Zika virus (ZIKV) (strain Zika SPH2015) M/Membrane protein (Fc)	Virus	HEK293
	Genome polyprotein is a smaller protein chain of covalent linkages that is a key component of virus survival and replication. Zika virus Membrane protein (HEK293, Fc) is the recombinant Virus-derived Zika virus Membrane protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Zika virus Membrane protein (HEK293, Fc) is 75 a.a., with molecular weight of ~35.2 kDa.

HY-P75660

	FCAR/CD89 Protein, Rat (HEK293, His) Immunoglobulin Alpha Fc Receptor; IgA Fc Receptor; CD89; FCAR	Rat	HEK293
	FCAR is an Fc fragment of the IgA receptor, also known as CD89. Fcars are found on the cell surface of myeloid cells, including neutrophils, monocytes, macrophages, and eosinophils. FCAR exerts proinflammatory effects by participating in PI3K and PLC-γ signaling. FCAR is also an important Fc receptor for neutrophils to kill tumor cells. FCAR/CD89 Protein, Rat (HEK293, His) is the recombinant rat-derived FCAR/CD89 protein, expressed by HEK293 , with C-His labeled tag. The total length of FCAR/CD89 Protein, Rat (HEK293, His) is 207 a.a., with molecular weight of 35-40 kDa.

HY-P703902

	Fc epsilon RI Protein, Human (ECD, His) Fc fragment of IgE; high affinity I; receptor for; alpha polypeptide	Human	HEK293

HY-P7806

	Fc gamma RIIIA/CD16a Protein, Cynomolgus (HEK293, His) rCynFc-gamma receptor 3A/CD16a, His; Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A; CD16a Antigen; Fc-Gamma RIII-Alpha; Fc-Gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc Receptor III-2; CD16a; FCGR3A; CD16A; FCG3; FCGR3; IGFR3	Cynomolgus	HEK293
	FCGR3A is a receptor for the Fc portion of immunoglobulin G that enhances antibody-dependent cell-mediated cytotoxicity and antibody-dependent viral infection. FCGR3A is also a potential immune oncogenic molecule and is related to the level of tumor immune infiltration. FCGR3A is often used as a biomarker with prognostic value in prostate cancer (PCa). Fc gamma RIIIA/CD16a Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Fc gamma RIIIA/CD16a protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Fc gamma RIIIA/CD16a Protein, Cynomolgus (HEK293, His) is 186 a.a., with molecular weight of 30-40 kDa.

HY-P7415

	TIM-3/HAVCR2 Protein, Human (HEK293, Fc) rHuTIM-3, Fc Chimera; TIMD-3; CD366; HAVCR2	Human	HEK293
	TIM3 Protein, Human (HEK293, Fc) is a type I transmembrane glycoprotein belonging to T Cell Immunoglobulin Mucin (TIM) family, and is involved in regulating innate and adaptive immunity.

HY-P7800

	CD162/PSGL-1 Protein, Mouse (HEK293, Fc) rMuCD162, C-Fc; PSGL-1; CD162; SELPLG; CLA;	Mouse	HEK293
	CD162/PSGL-1 Protein, Mouse (HEK293, Fc) is a recombinant mouse CD162 expressed in HEK 293 cells with a C-Fc tag at the C-terminus. CD162/PSGL-1 Protein plays an important role in immunity and homeostasis .

HY-P72603

	IgG2A Fc Protein, Mouse (HEK293) Ig gamma-2 chain C region; IgG2A Fc	Mouse	HEK293
	Ig gamma-2A chain C region (Immunoglobulin heavy chain gamma polypeptide) is one of the five types of mammalian immunoglobulin heavy chain: γ, δ, α, μ and ε. Heavy chain γ defines the classes of immunoglobulins IgG. IgG2A Fc Protein, Mouse (HEK293) is the recombinant mouse-derived IgG2A Fc protein, expressed by HEK293 , with tag free. The total length of IgG2A Fc Protein, Mouse (HEK293) is 232 a.a., with molecular weight of 30-35 kDa.

HY-P72604

	IgG2A Fc Protein, Rat (HEK293) Ig gamma-2 chain C region; IgG2A Fc	Rat	HEK293
	Ig gamma-2A chain C region (IgG2a) is one of the IgG antibodies subclasses and responses to an antigen. IgG2a plays a crucial role in the adaptive immune response. IgG2A Fc Protein, Rat (HEK293) is the recombinant rat-derived IgG2A Fc protein, expressed by HEK293 , with tag free. The total length of IgG2A Fc Protein, Rat (HEK293) is 225 a.a., with molecular weight of 30-35 kDa.

HY-P74900

	Hendra virus Glycoprotein/GP Protein (HEK293, Fc) Hendra virus (HeV) (isolate Horse/Autralia/Hendra/1994) Glycoprotein Protein (Fc)	Virus	HEK293
	The Hendra virus Glycoprotein/GP initiates infection by binding the virus to sialic acid-containing cell receptors. Upon binding, GP induces a conformational change, triggering fusion between the virion and cell membranes by the F protein. Hendra virus Glycoprotein/GP Protein (HEK293, Fc) is the recombinant Virus-derived Hendra virus Glycoprotein/GP protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Hendra virus Glycoprotein/GP Protein (HEK293, Fc) is 534 a.a., with molecular weight of ~86.3 kDa.

HY-P76665

	Statherin Protein, Human (HEK293, Fc) Statherin; STATH	Human	HEK293
	Statherin, a salivary protein, crucially regulates saliva's calcium salt supersaturation by inhibiting calcium phosphate salt precipitation. Beyond preventing crystallization, statherin significantly influences hydroxyapatite crystal formation on teeth, highlighting its dual role in dental health. It prevents undesirable mineral deposition and impacts tooth mineralization dynamics. Statherin Protein, Human (HEK293, Fc) is the recombinant human-derived Statherin protein, expressed by HEK293 , with C-mFc labeled tag. The total length of Statherin Protein, Human (HEK293, Fc) is 62 a.a., with molecular weight of ~36 KDa.

HY-P76725

	Amelotin Protein, Human (HEK293, Fc) Amelotin; AMTN	Human	HEK293
	Amelotin Protein is a key promoter of calcium phosphate mineralization, crucial in amelogenesis maturation. It plays a vital role in forming the compact and mineralized aprismatic enamel surface layer, emphasizing its crucial involvement in orchestrating molecular events for robust enamel structure during tooth maturation. Amelotin Protein, Human (HEK293, Fc) is the recombinant human-derived Amelotin, expressed by HEK293 , with C-mFc labeled tag. The total length of Amelotin Protein, Human (HEK293, Fc) is 193 a.a.,

HY-P77823

	PSMP Protein, Mouse (HEK293, Fc) Msmp; Psmp	Mouse	HEK293
	PSMP protein, acting as a CCR2 ligand, induces a robust chemotactic response and intracellular calcium mobilization in monocytes and lymphocytes, while having no impact on neutrophils. PSMP Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived PSMP protein, expressed by HEK293 , with C-hFc labeled tag. The total length of PSMP Protein, Mouse (HEK293, Fc) is 103 a.a., with molecular weight of 48-51 kDa.

HY-P77949

	GIP Protein, Mouse (HEK293, Fc) GIP; Incretin	Mouse	HEK293
	GIP protein is a potent stimulator of insulin secretion that critically regulates glucose homeostasis by promoting insulin release from pancreatic beta cells. GIP has limited inhibitory effects on gastric acid secretion and plays dual roles in nutrient sensing and metabolic regulation, particularly in postprandial glucose metabolism. GIP Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived GIP protein, expressed by HEK293 , with C-hFc labeled tag. The total length of GIP Protein, Mouse (HEK293, Fc) is 64 a.a., with molecular weight of 40-45 kDa.

HY-P78027

	PSMP Protein, Human (HEK293, Fc) Msmp; Psmp	Human	HEK293
	PSMP Protein acts as a ligand for CCR2, inducing chemotaxis and calcium mobilization. It attracts monocytes and lymphocytes, not neutrophils. It contributes to neuropathic pain and enhances synaptic transmission in dopamine neurons. PSMP Protein exists as a monomer or homodimer, binding to endothelial cells via proteoglycans. It interacts with TNFAIP6. PSMP Protein, Human (HEK293, Fc) is the recombinant human-derived PSMP protein, expressed by HEK293, with C-hFc labeled tag. The total length of PSMP Protein, Human (HEK293, Fc) is 103 a.a., with molecular weight of 45-50 kDa.

HY-P78581

	Mer Protein, Cynomolgus (HEK293, Fc) MERTK; Mer	Cynomolgus	HEK293
	Mer protein is a receptor tyrosine kinase that transduces signals by binding to ligands such as LGALS3, TUB, TULP1, or GAS6, regulating cell survival, migration, differentiation, and apoptotic cell phagocytosis (endocytosis). Ligand binding induces autophosphorylation of MERTK, creating a docking site for downstream molecules. Mer Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived Mer protein, expressed by HEK293 , with C-hFc labeled tag. The total length of Mer Protein, Cynomolgus (HEK293, Fc) is 485 a.a., with molecular weight of approximately 150 kDa.

HY-P7538

	APRIL/TNFSF13 Protein, Mouse (HEK293, Fc) rMuAPRIL/TNFSF13, N-Fc; CD256; TALL2; APRIL; TNFSF13	Mouse	HEK293
	APRIL protein (CD256) is a ligand in the tumor necrosis factor (TNF) family that can induce proliferation, regulate tumor cell growth, and may participate in mononuclear/macrophage-mediated immune process. APRIL protein is produced by myeloid cells and their precursors to accelerate cell maturation and peripheral rupture. APRIL protein has been widely used in the study of lymphatic malignancies. Mouse APRIL protein is a type II membrane protein with cytoplasmic domain, hydrophobic transmembrane domain and extracellular domain. APRIL/TNFSF13 Protein, Mouse (HEK293, Fc) is produced by HEK293 cells (A96-K240) with N-terminal Fc-tag.

HY-P7632

	B7-1/CD80 Protein, Mouse (HEK293, Fc) rMuB7-1, C-Fc; Activation B7-1 antigen	Mouse	HEK293
	B7-1/CD80 Protein, Mouse (HEK293, Fc) is not only expressed on APCs, but also is expressed on T cells. B7-1:PD-L1 interaction can inhibit T cell proliferation and cytokine production.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13690S1

Mitotane-13C6

Mitotane- ¹³C₆ is the ¹³C labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

HY-13690S2

Mitotane-d8

Mitotane-d₈ is the deuterium labeled Mitotane[1]. Mitotane (2,4′-DDD), an isomer of DDD and derivative of dichlorodiphenyltrichloroethane (DDT), is an antineoplastic agent, can be used to research adrenocortical carcinoma. Mitotane exert its adrenocorticolytic effect at least in part through lipotoxicity induced by intracellular free cholesterol (FC) accumulation. Mitotane can have direct pituitary effects on corticotroph cells. Mitotane can induce CYP3A4 gene expression via steroid and xenobiotic receptor (SXR) activation, and has agent-agent interactions[2][3][4][5].

HY-B0723S

Ospemifene D4
Ospemifene-d₄ is a deuterium labeled Ospemifene. Ospemifene is a selective and orally active estrogen receptor modulator for the prevention of osteoporosis with IC50 values of 827 nM and 1633 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene has bone-sparing, antitumor, and cholesterol-lowering effects[1][2].

HY-B0005S1

Toremifene-d6 hydrochloride
Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.07 µM and 2.6 µM, respectively .

HY-B0005AS

Toremifene-d6
Toremifene-d₆ is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80981

	FCGR1A Antibody Fc-gamma RI; FcRI; Fc-gamma RIA; FcgammaRIa; CD64	WB, IHC-P, FC	Human
	FCGR1A Antibody is an unconjugated, approximately 43 kDa, rabbit-derived, anti-FCGR1A monoclonal antibody. FCGR1A Antibody can be used for: WB, IHC-P, FC expriments in human background without labeling.

HY-P81202

	CD16 Antibody FCG3A_HUMAN; Low affinity immunoglobulin gamma Fc region receptor III-A; CD16a antigen; Fc-gamma RIII-alpha; Fc-gamma RIII; Fc-gamma RIIIa; FcRIII; FcRIIIa; FcR-10; IgG Fc receptor III-2; CD_antigen: D16a; FCGR3A; CD16A; FCG3; FCGR3; IGFR3.	WB, ELISA, IHC-P, IHC-F, FC, ICC/IF	Human, Mouse, Rat
	CD16 Antibody is an unconjugated, approximately 27 kDa, rabbit-derived, anti-CD16 polyclonal antibody. CD16 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, and predicted: pig, cow, rabbit, sheep background without labeling.

HY-P82215

	CD89 Antibody (YA1960) FCAR; CD89; Immunoglobulin alpha Fc receptor; IgA Fc receptor; CD89	WB, IHC-P, ICC/IF, IP, FC	Human
	CD89 Antibody (YA1960) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1960), targeting CD89, with a predicted molecular weight of 32 kDa (observed band size: 70 kDa). CD89 Antibody (YA1960) can be used for WB, IHC-P, ICC/IF, IP, FC experiment in human background.

HY-P83505

	CD32 Antibody (YA3250) FCGR2A; CD32; FCG2; FCGR2A1; IGFR2; Low affinity immunoglobulin gamma Fc region receptor II-a; IgG Fc receptor II-a; CDw32; Fc-gamma RII-a; Fc-gamma-RIIa; FcRII-a; CD32	WB, IHC-P	Human
	CD32 Antibody (YA3250) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3250), targeting CD32, with a predicted molecular weight of 35 kDa (observed band size: 43 kDa). CD32 Antibody (YA3250) can be used for WB, IHC-P experiment in human background.

HY-P83712M

	Rat Anti-Mouse CD16/32 Antibody (FITC) CD16a/b; CD32; CD32A/B; Fc fragment of IgG low affinity IIa/b receptor; Fc fragment of IgG low affinity IIIa/b receptor; Fc fragment of IgG low affinity IIIb receptor; Fc gamma receptor III A/B; FCG2A; FcGR; FCGR2A/BFCGR3; FCGR3A/B; Fc gamma RIIa/b	FC	Mouse

HY-P81527

	FCRL4 Antibody (YA1272) FCRL4; FCRH4, IFGP2, IRTA1; Fc receptor-like protein 4; CD307d; FcR-like protein 4; FcRL4; Fc receptor homolog 4 (FcRH4); IFGP family protein 2 (hIFGP2); Immune receptor translocation-associated protein 1	IHC-P	Human
	FCRL4 Antibody (YA1272) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1272), targeting FCRL4. FCRL4 Antibody (YA1272) can be used for IHC-P experiment in human background.

HY-P81870

	CD32B Antibody (YA1615) Fc fragment of IgG; low affinity IIb; receptor (CD32); CD32; FCG2; CD32B; FCGR2; IGFR2	WB, IHC-P	Human, Rat
	CD32B Antibody (YA1615) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1615), targeting CD32B, with a predicted molecular weight of 34 kDa (observed band size: 44 kDa). CD32B Antibody (YA1615) can be used for WB, IHC-P experiment in human, rat background.